文献速递乳腺癌放疗

乳腺癌术后2周辅助全乳/胸壁和/或区域淋巴结放疗的2期研究

A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2017-12-16

这项2期研究前瞻性纳入50例乳腺癌术后患者,评估2周大分割辅助全乳/胸壁和/或区域淋巴结放疗的可行性与早期毒性。方案为34 Gy分10次,保乳患者追加10 Gy分5次;中位随访39个月,急性2级和3级皮肤毒性分别为32%和2%,3年无病生存率和总生存率分别为94%和96%,患者经济负担显著降低。

要点

  • 2周大分割放疗方案:34 Gy分10次,保乳患者追加10 Gy分5次。
  • 急性2级和3级皮肤毒性发生率分别为32%和2%。
  • 3年无病生存率和总生存率分别为94%和96%。

核心结论

  • 2周大分割辅助放疗对乳腺癌患者可行,急性及晚期皮肤毒性谱与3周方案相似。
  • 2周治疗可减轻患者及家庭的经济负担。
  • 需要长期随访数据及前瞻性对照研究来强化这些结果。

研究设计与样本

  • 2013年6月至2014年10月前瞻性纳入50例乳腺癌术后(乳房切除或保乳手术)患者。
  • 放疗剂量为34 Gy分10次(2周内),保乳患者追加10 Gy分5次(1周内)。
  • 主要目标为获取急性毒性率和美容结局的估计值,用于设计后续3期对照研究。

主要发现

  • 中位随访39个月(范围14-48),平均年龄51岁(范围26-75),左侧肿瘤25例(50%)。
  • 全乳切除加腋窝清扫40例(80%),保乳手术10例(20%)。
  • 急性2级和3级皮肤毒性分别见于16例(32%)和1例(2%)患者。
  • 保乳患者中2级皮肤和皮下毒性分别见于2例(20%)和1例(10%),2级水肿1例(10%)。
  • 保乳患者美容结局优良8例(80%),一般或差2例(20%)。

关键数值与推荐

  • 放疗剂量:34 Gy分10次(2周内),保乳追加10 Gy分5次(1周内);对照标准治疗为35 Gy分15次(3周内)。
  • 急性皮肤毒性按RTOG急性放射毒性评分标准记录。
  • 3年无病生存率94%,总生存率96%。

临床怎么用

  • 2周大分割辅助放疗可作为乳腺癌术后放疗的可行选择,尤其适用于资源有限、患者需长途就医的中心。
  • 治疗前需评估保乳患者追加照射的必要性,并按照RTOG标准监测急性皮肤毒性。
  • 该方案可能降低患者经济负担,但需结合长期随访和前瞻性对照研究结果谨慎推广。

局限性

  • 单臂2期研究,样本量50例,随访时间有限(中位39个月)。
  • 需要长期随访数据及前瞻性对照研究来强化结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the results in terms of feasibility and early toxicity of hypofractionated adjuvant whole breast/chest wall and/or regional nodal radiation therapy for patients with breast cancer. METHODS AND MATERIALS: From June 2013 to October 2014, 50 patients with breast cancer after mastectomy or after breast conservation surgery (BCS) were prospectively included. The institutional ethics committee approved the study, which was registered with ClinicalTrials.gov (ClinicalTrials.gov identifier no. NCT02460744). Treatment planning was performed using a simulator with 2 tangential fields to the breast/chest wall and an incident field to the supraclavicular fossa. The radiation dose delivered was 34 Gy in 10 fractions within 2 weeks, followed by a boost of 10 Gy in 5 fractions within 1 week for patients who underwent BCS. Acute skin toxicities were recorded during and after treatment according to the Radiation Therapy Oncology Group acute radiation toxicity scoring criteria. The primary objective was to obtain estimates of the acute toxicity rates and cosmetic outcomes that could be used to design a subsequent phase III comparative study. Acute skin and late toxicities were recorded during and after treatment. Cosmetic outcomes were assessed before and after treatment and during the regular follow-up period. A cost/benefit analysis was also performed and compared with that for standard treatment of 35 Gy in 15 fractions within 3 weeks. RESULTS: The median follow-up was 39 months (range 14-48). The mean age was 51 years (range 26-75). A left-sided tumor was present in 25 patients (50%). Total mastectomy with axillary clearance was performed in 40 (80%) and BCS in 10 (20%) patients. Acute grade 2 and 3 skin toxicity was seen in 16 (32%) and 1 (2%) patient, respectively. In the BCS patients, grade 2 skin and subcutaneous toxicity was seen in 2 (20%) and 1 (10%) patient, respectively. Grade 2 edema was seen in 1 patient (10%). The cosmesis was excellent or good in 8 (80%) and fair or poor in 2 (20%) patients. The cost/benefit analysis revealed significantly less financial burden on the patients with 2 weeks of treatment. Disease-free and overall survival at 3 years was 94% and 96%, respectively. CONCLUSIONS: Hypofractionated radiation therapy within 2 weeks appears to be feasible for patients with breast cancer and was associated with acute and late skin toxicity profiles similar to those observed with 3 weeks of treatment. The financial burden on the patient and family could be reduced with 2 weeks of treatment. Long-term follow-up data and a prospective comparative study are needed to strengthen these results. Hypofractionation might help radiation centers worldwide to meet the increasing need for radiation for breast cancer, especially in developing countries where resources are limited and patients must travel long distances for treatment.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Yadav BS, Sharma SC. A Phase 2 Study of 2 Weeks of Adjuvant Whole Breast/Chest Wall and/or Regional Nodal Radiation Therapy for Patients With Breast Cancer. Int J Radiat Oncol Biol Phys. 2017. PMID: 29485066. doi:10.1016/j.ijrobp.2017.12.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。